Nasdaq dbtx.

Sep 5, 2023 · Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ... The stock was up 19.45% to $8.66 in after-hours trading. Pfizer-BioNTech COVID-19 Vaccine 100% Effective In Adolescent Population. Pfizer Inc. (NYSE:PFE) and its German partner BioNTech SE (NASDAQ ...Nasdaq News: This is the News-site for the company Nasdaq on Markets Insider Indices Commodities Currencies StocksFind the latest dividend history for Decibel Therapeutics, Inc. Common Stock (DBTX) at Nasdaq.com.Gainers Akouos, Inc. (NASDAQ:AKUS) shares jumped 89.4% to $13.27. Eli Lilly And Co (NYSE:LLY) agreed to acquire Akouos for a 78% premium over M...

DBTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Decibel Therapeutics, Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Decibel Therapeutics, Inc. (NASDAQ: DBTX) to Regeneron Pharmaceuticals, Inc. is fair to Decibel shareholders.Find the latest Institutional Holdings data for Decibel Therapeutics, Inc. Common Stock (DBTX) at Nasdaq.com.Company profile page for Decibel Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at March 2023, Decibel Therapeutics had cash of US$88m and no debt ...

About Nasdaq Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software, and services enables clients ...Fintel reports that on May 12, 2023, HC Wainwright & Co. reiterated coverage of Decibel Therapeutics (NASDAQ:DBTX) with a Buy recommendation. Analyst Price Forecast Suggests 272.02% Upside. As of ...Director. 02/17/2021. Acquisition (Non Open Market) Indirect. 3,278,526. 2,732,106. Back to DBTX Overview. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the ...BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage company developing treatments to restore and improve hearing and balance, presented preclinical data ...

Find the latest Earnings Report Date for Decibel Therapeutics, Inc. Common Stock (DBTX) at Nasdaq.com.

BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ...BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Dec 3, 2023 · Decibel Therapeutics (NASDAQ:DBTX) has a recorded net income of -$63.01 million. DBTX has generated -$2.53 earnings per share over the last four quarters. What is Decibel Therapeutics's EPS forecast for next year? BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

May 2, 2022 · BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ... BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ...Aug 28, 2023 · Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ... USA, PLSE, NASDAQ. 080134288, Synergy Chc Corp. USA, SNYR, OTHER OTC Market. 080143728, Decibel Therapeutics, Inc. USA, DBTX, NASDAQ. 080144027, Ulta Beauty, ...Quick Take. Decibel Therapeutics (NASDAQ:DBTX) has filed to raise $100 million in an IPO of its common stock, according to an amended S-1 registration …BOSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that John Lee, chief development officer, and Lis Leiderman, M.D., MBA, chief financial …

Mar 29, 2021 · BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

Decibel Therapeutics Inc. (Nasdaq: DBTX) has extended its research collaboration with Regeneron Pharmaceuticals Inc. (Nasdaq: RGEN) through mid-November 2023. Regeneron will pay Decibel an ...BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Nasdaq Stock Market LLC. 2023/10/12, 25-NSE, CPST, Capstone Green Energy Corp ... Sunlight Financial Holdings Inc. 2023/10/10, 15-12G, DBTX, Decibel Therapeutics ...BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...On July 20, investment advisory Deutsche Bank maintained a Buy rating on Indie Semiconductor, Inc. (NASDAQ:INDI) stock and lowered the price target to $10 from $11. Analyst Ross Seymore issued the ...BOSTON, May 13, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

DBTX Latest Real Time Trades. Select time range to see more trades: Last 100 Trades. NLS Time (ET) NLS Price. NLS Share Volume. 16:00:04. $ 4.33. 42.

Decibel Therapeutics Inc (NASDAQ: DBTX) announced the presentation of preclinical data on DB-OTO, its lead gene therapy product candidate. DB-OTO is a dual-vector adeno-associated candidate ...

BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...DBTX, A, Decibel Therapeutics, Inc. 0.00. ABEO, B, Abeona Therapeutics Inc. 11.60. GRCL, C, Gracell Biotechnologies Inc. 6.93. PHXM, C, PHAXIAM Therapeutics ...Based on analysts offering 12 month price targets for DBTX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ...Every investor in Decibel Therapeutics, Inc. (NASDAQ:DBTX) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see ... Decibel Therapeutics ( NASDAQ: DBTX) is an early-stage gene therapy company focused on developing new medicines for hearing and balance disorders. The company’s biological hypothesis is centered ...BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

Aug 9, 2023 · TARRYTOWN, N.Y. and BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Decibel Therapeutics, Inc. (NASDAQ: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced a definitive agreement ... BOSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that John Lee, chief development officer, and Lis Leiderman, M.D., MBA, chief financial …Decibel Therapeutics, Inc. Common Stock (DBTX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.Instagram:https://instagram. loser stock todayaflac competitorslithium stocks etfpopular banks in arizona Translating rapid advances in hearing science to meet the urgent needs of hundreds of millions worldwide with disabling hearing loss. planet firmessagncstock Decibel Therapeutics, Inc. (Nasdaq - DBTX) Under the terms of the Merger Agreement, Decibel will be acquired by Regeneron Pharmaceuticals, Inc. (Nasdaq - REGN). Decibel shareholders will receive ...Mar 21, 2023 · BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ... prhsx holdings Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today ...The share price of Decibel Therapeutics Inc. (DBTX) is $4.91 (NASDAQ) as of 04-Oct-2023 09:30 EST. Decibel Therapeutics Inc. (DBTX) has given a return of 40.29% in the last 1 years. What is the market cap of Decibel Therapeutics Inc. (DBTX)?Decibel intends to initiate the Phase 1/2 clinical trial of DB-OTO in the first half of 2023. BOSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage ...